Matrix metalloprotease-2 and -9 concentration and activity in serum and culture medium samples: A methodological reappraisal

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 10, 2007, Pages 1292-1298

  Colotti, Chiara ^a   Angeli, Valeria ^b   Del Ry, Silvia ^b   Maltinti, Maristelli ^b   Vittorini, Simona ^b   Giannessi, Daniela ^b  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

ELISA; Enzymatic assay; Matrix metalloproteases (MMP); MMP serum levels; Restenosis

Indexed keywords

GELATINASE A; GELATINASE B;

ACCURACY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; CULTURE MEDIUM; DISEASE COURSE; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERPLASIA; INTIMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SAPHENOUS VEIN; SENSITIVITY ANALYSIS; TISSUE CULTURE;

CARDIOVASCULAR PHYSIOLOGY; CULTURE MEDIA; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; ORGAN CULTURE TECHNIQUES; REPRODUCIBILITY OF RESULTS; SAPHENOUS VEIN; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUNICA INTIMA;

EID: 35048881892     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.283     Document Type: Article

References (19)

1. Woessner JF. The family of matrix metalloproteases. Ann NY Acad Sci 1994;732:11-21.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteases in cancer progression. Nat Rev Cancer 2002;2:161-74.
3. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteases: an overview. Mol Cell Biochem 2003;253:269-85.
4. Visse R, Nagase H. Structure, function, and biochemistry of matrix metalloproteases and tissue inhibitors of metalloproteases. Circ Res 2003;92:827-39.
5. Somerville RP, Oblander SA, Apte SS. Matrix metalloproteases: old dogs with new tricks. Genome Biol 2003;4:216.1-11.
6. Nagase H, Visse R, Murphy G, Structure and function of matrix metalloproteases and TIMPs. Cardiac Res 2006;69:562-73.
7. Jung K, Nowak L, Lein M, Henke W, Schnorr D, Loening SA. Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors. Clin Chem 1996;42:2043-4.
8. Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D, et al. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 (MMP2; MMP9) and tissue inhibitor of metalloproteinase 2 TIMP2 in blood. Clin Chem 1998;44:1060-2.
9. Lein M, Nowak L, Jung K, Koenig F, Lichtinghagen R, Schnorr D, et al. Analytical aspect regarding the measurement of matrix metalloproteinases and their inhibitors in blood. Clin Biochem 1997;30:491-6.
10. Rouy D, Ernens I, Jeanty C, Wagner DR. Plasma storage at -80°C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 2005;338:294-8.
11. Mandal M, Mandal A, Das S, Chakraborti T, Chakraborti S. Clinical implications of matrix metalloproteases. Mol Cell Biochem 2003;252:305-29.
12. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, Shimada K. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 2002;161:185-92.
13. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, for tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005;150:484-7.
14. Alcocer F, Whitley D, Salazar J, Jordan W, Bland KI. Mutual exclusion of apoptosis and HSP70 in human vein intimal hyperplasia in vitro. J Surg Res 2001;96:75-80.
15. Pilo A, Zucchelli GC, Malvano R, Masini S. Main features of computer algorithms for RIA data reduction; comparison of some different approaches for the interpolation of the dose-response curve. J Nucl Med Allied Sci 1982;26:235-48.
16. Manoj CR, Martin DS, Redetzke RA, Eyster K. A method for the extraction of high-quality RNA and protein from single small samples of arteries and veins preserved in RNA later. J Pharmacol Toxicol Methods 2002;47:87-92.
17. Kranzhöfer A, Baker AH, George SJ, Newby AC. Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein. Arterioscler Thromb Vasc Biol 1999;19:255-65.
18. Paisley AN, O'Callaghan CJ, Lewandowski KC, Parkinson C, Roberts ME, Drake WM, et al. Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly. J Clin Endocrinol Metab 2006;22:1-13.
19. Wallace YS, McEniery CM, Dakham Z, Pusalkar P, Maki-Petaja K, Ashby MJ, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372-8.